PE20161222A1 - Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato - Google Patents

Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Info

Publication number
PE20161222A1
PE20161222A1 PE2016001604A PE2016001604A PE20161222A1 PE 20161222 A1 PE20161222 A1 PE 20161222A1 PE 2016001604 A PE2016001604 A PE 2016001604A PE 2016001604 A PE2016001604 A PE 2016001604A PE 20161222 A1 PE20161222 A1 PE 20161222A1
Authority
PE
Peru
Prior art keywords
inden
pyrimidin
dihydro
hydroxyciclopentil
methylsulfamate
Prior art date
Application number
PE2016001604A
Other languages
English (en)
Spanish (es)
Inventor
Ian G Armitage
Marianne Langston
Martin Ian Cooper
Reenu Chopra
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20161222A1 publication Critical patent/PE20161222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2016001604A 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato PE20161222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14

Publications (1)

Publication Number Publication Date
PE20161222A1 true PE20161222A1 (es) 2016-12-01

Family

ID=42396430

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016001604A PE20161222A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato
PE2011001962A PE20120907A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001962A PE20120907A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Country Status (18)

Country Link
US (2) US9187482B2 (enExample)
EP (2) EP3091020B1 (enExample)
JP (3) JP2012526808A (enExample)
KR (2) KR20170102381A (enExample)
CN (2) CN102421780A (enExample)
AU (1) AU2010248151B2 (enExample)
BR (1) BRPI1012142A2 (enExample)
CA (1) CA2761256C (enExample)
IL (1) IL216201A (enExample)
MX (1) MX2011012108A (enExample)
NZ (2) NZ621128A (enExample)
PE (2) PE20161222A1 (enExample)
PH (1) PH12015501925A1 (enExample)
RU (1) RU2562245C2 (enExample)
SG (2) SG10201402148SA (enExample)
UA (1) UA108986C2 (enExample)
WO (1) WO2010132110A1 (enExample)
ZA (1) ZA201108347B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
KR101925902B1 (ko) * 2007-08-02 2018-12-06 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ1 활성화 효소 억제제의 합성 방법
NZ621128A (en) 2009-05-14 2015-08-28 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
EP2635287A4 (en) * 2010-11-05 2014-06-04 Millennium Pharm Inc NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION
EA031067B1 (ru) * 2011-08-24 2018-11-30 Миллениум Фармасьютикалз, Инк. ИНГИБИТОРЫ Nedd8-АКТИВИРУЮЩЕГО ФЕРМЕНТА
AU2012321106C1 (en) 2011-11-03 2016-11-24 Takeda Pharmaceutical Company Limited Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
EP3536692B1 (en) 2012-02-17 2021-04-07 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CA2880813A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. Indole-substituted pyrrolopyrimidinyl inhibitors of uba6
CN104822844B (zh) 2012-10-01 2019-05-07 米伦纽姆医药公司 预测对抑制剂的反应的生物标记物和方法以及其用途
CN105407973A (zh) 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与
EP3016934B1 (en) 2013-07-02 2018-01-10 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
EP3517112B1 (en) 2014-07-01 2021-04-07 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
EP3684363A4 (en) * 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
EP3930720A4 (en) * 2019-02-26 2022-12-28 Millennium Pharmaceuticals, Inc. COMPOUNDS USEFUL AS ADJUVANTS
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
KR20040028657A (ko) 2000-10-18 2004-04-03 파마셋, 리미티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드
AU2002364536B2 (en) 2001-12-07 2008-10-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
WO2003106477A1 (en) 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1730122A2 (en) 2004-03-30 2006-12-13 Taisho Pharmaceutical Co., Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CA2596424C (en) 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
ES2593433T3 (es) * 2006-02-02 2016-12-09 Millennium Pharmaceuticals, Inc. Inhibidores de las enzimas activadoras E1
DE602007009998D1 (de) 2006-08-08 2010-12-02 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1-aktivierenden enzyme
KR101925902B1 (ko) * 2007-08-02 2018-12-06 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ1 활성화 효소 억제제의 합성 방법
NZ621128A (en) 2009-05-14 2015-08-28 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
AU2012321106C1 (en) 2011-11-03 2016-11-24 Takeda Pharmaceutical Company Limited Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
CN105407973A (zh) 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与

Also Published As

Publication number Publication date
MX2011012108A (es) 2011-12-08
RU2011150826A (ru) 2013-06-20
ZA201108347B (en) 2014-05-26
EP3091020A3 (en) 2017-01-11
NZ621128A (en) 2015-08-28
US20160030432A1 (en) 2016-02-04
EP3091020B1 (en) 2020-12-30
US20110021544A1 (en) 2011-01-27
IL216201A0 (en) 2012-01-31
JP2017105816A (ja) 2017-06-15
IL216201A (en) 2015-11-30
KR20120024715A (ko) 2012-03-14
BRPI1012142A2 (pt) 2016-03-29
EP3091020A2 (en) 2016-11-09
CN102421780A (zh) 2012-04-18
AU2010248151B2 (en) 2016-07-14
NZ596470A (en) 2014-04-30
WO2010132110A1 (en) 2010-11-18
PH12015501925A1 (en) 2018-01-22
US9187482B2 (en) 2015-11-17
JP2012526808A (ja) 2012-11-01
SG10201402148SA (en) 2014-07-30
CN104016987A (zh) 2014-09-03
KR20170102381A (ko) 2017-09-08
US10016427B2 (en) 2018-07-10
CA2761256A1 (en) 2010-11-18
RU2562245C2 (ru) 2015-09-10
UA108986C2 (uk) 2015-07-10
EP2430026A1 (en) 2012-03-21
PE20120907A1 (es) 2012-08-18
JP2015096547A (ja) 2015-05-21
SG175929A1 (en) 2011-12-29
US20170000792A9 (en) 2017-01-05
AU2010248151A1 (en) 2011-12-01
CA2761256C (en) 2021-01-05

Similar Documents

Publication Publication Date Title
PE20161222A1 (es) Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
CO7170131A2 (es) Compuestos de heterociclilo
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
UY32848A (es) Compuestos heterocíclicos de oxima
EA201101618A1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
PE20121499A1 (es) Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
MX2009010568A (es) Formas solidas de pemetrexed.
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
BR112013029999A2 (pt) derivados de tiazol
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
BR112012006172A2 (pt) derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
PE20080338A1 (es) 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
SV2011003846A (es) Polimorfo b de la n-(2-aminofenil)-4- [n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek
EA201391524A1 (ru) Производные гликозида и их применение
CR20120311A (es) Derivados de sulfonamida heterocíclicos
AR084882A1 (es) Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia

Legal Events

Date Code Title Description
FD Application declared void or lapsed